ECG
IRLA

EPIQ Capital Group’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

EPIQ Capital Group’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$1.54M Sell
4,124
-6
-0.1% -$1.8K 0.4% 30
2024
Q3 		$641K Sell
4,130
-132
-3% -$18.9K 0.18% 40
2024
Q2 		$639K Buy
4,262
+33
+0.8% +$5.96K 0.23% 37
2024
Q1 		$897K Sell
4,229
-122
-3% -$30.3K 0.36% 26
2023
Q4 		$914K Sell
4,351
-282
-6% -$56.5K 0.42% 20
2023
Q3 		$1.04M Sell
4,633
-33
-0.7% -$8.62K 0.54% 19
2023
Q2 		$1.4M Sell
4,666
-126
-3% -$39.2K 0.71% 17
2023
Q1 		$1.5M Sell
4,792
-489
-9% -$95.7K 0.75% 16
2022
Q4 		$673K Sell
5,281
-5,002
-49% -$836K 0.37% 24
2022
Q3 		$2.73M Sell
10,283
-6,095
-37% -$2.32M 1.35% 14
2022
Q2 		$7.27M Sell
16,378
-4,019
-20% -$2.84M 2.85% 10
2022
Q1 		$20M Sell
20,397
-949
-4% -$1.29M 5.47% 8
2021
Q4 		$53.9M Buy
21,346
+1,578
+8% +$9.63M 9.57% 3
2021
Q3 		$362M Buy
19,768
+940
+5% +$14.9M 37.45% 1
2021
Q2 		$200M Buy
18,828
+549
+3% +$4.6M 20.85% 2
2021
Q1 		$132M Buy
18,279
+744
+4% +$5.35M 14.71% 3
2020
Q4 		$97.4M Buy
17,535
+461
+3% +$4.08M 15.42% 2
2020
Q3 		$171M Buy
17,074
+360
+2% +$3.27M 24.43% 2
2020
Q2 		$155M Buy
16,714
+742
+5% +$6.8M 26.08% 2
2020
Q1 		$146M Buy
15,972
+255
+2% +$2.52M 43.1% 1
2019
Q4 		$176M Buy
+15,717
New +$94.8M 43.18% 1

Other funds holding IRLA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return

EPIQ Capital Group's IRLA Position: Q4 2024 in Review

EPIQ Capital Group reduced its IRulya Therapeutics Inc. Common Stock (IRLA) stake by 0.15% in Q4 2024, selling an estimated $1.8K and leaving 4,124 shares worth $1.54M. The position accounts for 0.4% of the portfolio, ranked #30.

EPIQ Capital Group first reported a position in IRLA in Q4 2019 and has held it in 21 quarters since. The position peaked at $362M in Q3 2021. 33 funds tracked by Wall St. Rank hold IRLA as of Q4 2024.

  • EPIQ Capital Group held 4,124 shares of IRulya Therapeutics Inc. Common Stock worth $1.54M as of Q4 2024.
  • EPIQ Capital Group sold 6 IRulya Therapeutics Inc. Common Stock shares in Q4 2024, an estimated $1.8K.
  • IRulya Therapeutics Inc. Common Stock made up 0.4% of EPIQ Capital Group's portfolio in Q4 2024, its #30 holding.
  • EPIQ Capital Group first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and has held it in 21 quarters since.
  • EPIQ Capital Group's IRulya Therapeutics Inc. Common Stock position peaked at $362M in Q3 2021.
  • 33 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q4 2024.

Based on EPIQ Capital Group's 13F filing for Q4 2024, filed 7 Feb 2025.